Bydureon BCise vs Trulicity

Bydureon (exenatide extended-release) and Trulicity (dulaglutide) are both once-weekly injectable GLP-1 receptor agonists used for type 2 diabetes. Bydureon, approved in 2012, reformulated the first-generation GLP-1 agonist exenatide into a sustained-release microsphere injection. Trulicity, approved in 2014, uses dulaglutide, a GLP-1 analogue fused to a modified immunoglobulin fragment that extends its half-life. Both medications are designed to improve glycemic control as adjuncts to diet and exercise.

In clinical studies, dulaglutide has generally demonstrated comparable or modestly superior HbA1c reductions relative to exenatide ER. The AWARD-1 trial showed dulaglutide 1.5 mg achieved HbA1c reductions of approximately 1.5% over 26 weeks, while exenatide ER 2 mg achieved approximately 1.0% in the same study. Weight loss was observed with both agents, though neither is FDA-approved specifically for weight management. These results suggest dulaglutide may offer a clinical advantage, though individual responses can vary.

Trulicity's pre-filled single-dose pen has generally been considered more convenient than older Bydureon formulations, which required reconstitution. The Bydureon BCise autoinjector improved the preparation process, but injection site reactions including nodules remain more commonly reported with exenatide ER due to its microsphere delivery. Both medications carry standard GLP-1 class warnings including risks of pancreatitis and thyroid C-cell tumors in animal studies. For patients choosing between these two older weekly GLP-1 options, Trulicity is often preferred in current clinical practice, though patients should consult their healthcare provider about which option best fits their needs.